Trump’s Drug Price Deals

The Trump administration’s drug pricing push is moving through a new phase, with confidential agreements in place and questions still unresolved about implementation, expansion and congressional action.

What you’ll learn

• How the administration’s most-favored-nation drug pricing approach has evolved
• What is known about the deals reached with major drugmakers
• What policy, regulatory and legislative questions could shape what comes next

Why this matters

Drug pricing remains a major pressure point for the health care industry, with potential implications for manufacturers, payers, providers and policymakers. As the administration pushes to expand and potentially codify its approach, POLITICO Pro helps health care organizations track how policy developments could shape strategy, planning and stakeholder engagement.

Fill out the form to read the full POLITICO Pro analysis.